Clinical Trial Update: Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of inhaled BEA 2180 BR in patients with chronic obstructive pulmonary disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BEA 2180 BR

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED